Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis exec Richard Smith joins EMD Serono

He becomes senior vice president and head of US fertility and endocrinology

EMD Serono Richard SmithMerck KGaA's US biopharmaceutical business EMD Serono has appointed Richard Smith as senior vice president and head of US fertility and endocrinology.

Smith will take on responsibility for the two businesses as well as the firm's fertility technologies division, which launched its first medical device last year.

He joins EMD Serono from Novartis, where he spent the last 18 years in a series of roles across the company's commercial business, most recently as vice president and US head of sales and operations of its cardiovascular franchise.

Prior to this role, Smith served as executive director and head of Novartis' transplant franchise, as well as positions in customer segment marketing, strategy and commercial operations for specialty medicines, brand managed markets strategy, and pricing and contracting for its neuroscience franchise.

Gary Zieziula, president and managing director of EMD Serono, said: “We have a longstanding focus on providing comprehensive solutions in the areas of fertility and endocrinology care through innovative products as well as financial, educational and emotional support.

“Adding Richard's expertise, passion and industry knowledge to our strong and committed team will ensure that we are well-positioned to further meet the needs of patients and customers.”

25th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics